You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 10,342,866


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,342,866
Title:Compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants
Abstract: Small molecule integrin ligand mimetics facilitate integrin-ligand interactions, which may be used to prepare vaccines, adoptive cell therapies, immunotherapies for cancer, and a variety of other conditions. As integrin mediated cell-cell interactions are critical to antigen presentation and effector cell killing, increasing the efficiency of integrin receptor-ligand interactions will stabilize the immune synapse and improve effector functions. Compositions and methods including the mimetics enhance: (1) the priming of vaccines (including, but not limited to, cancer vaccines); (2) cytolytic activity of adoptive cell therapies (including, but not limited to .gamma..delta.T-cells, CTLs, NK, iNKT); (3) immunotherapies (including, but not limited to, negative checkpoint blockage strategies such as anti-CTLA-4 and anti-PD-1); and (4) biologic therapies (including, but not limited, to trastuzumab and rituxamab), whereby the mechanism-of-action includes antibody dependent cellular cytotoxicity (ADCC).
Inventor(s): Woodside; Darren G. (Houston, TX), Vanderslice; Peter (Houston, TX), Marathi; Upendra K. (Houston, TX)
Assignee: 7 HILLS INTERESTS LLC (Houston, TX) TEXAS HEART INSTITUTE (Houston, TX)
Application Number:15/140,711
Patent Claims:1. A pharmaceutical composition comprising: a therapeutic antibody, and one activating compound or a plurality of activating compounds of the general Formula (I): R.sup.1-M.sup.1-N(R.sup.2)-M.sup.2-M.sup.3-M.sup.4-M.sup.5-M.sup.6-R.sup.- 3 (I) wherein: R.sup.1 is selected from the group consisting of aryl and aralkyl, R.sup.2 is alkyl, aryl, or aralkyl, M.sup.1 is CH.sub.2, M.sup.2 is CO, M.sup.3 is O, S, or NR.sup.6, where R.sup.6 when present is hydrogen or lower alkyl, M.sup.4 is absent or CH.sub.2, M.sup.5 is absent or (CR.sup.11R.sup.12) where R.sup.11 is hydrogen, R.sup.12 is selected from the group consisting of hydrogen, NR.sup.21CONR.sup.22R.sup.23, NR.sup.21COR.sup.24, NR.sup.21SO.sub.2R.sup.24, NR.sup.21COOR.sup.24, OCOR.sup.24, OR.sup.24, O(CH.sub.2CH.sub.2O).sub.sR.sup.24, COOR.sup.24, alkyl, and hydroxyalkyl, where s is an integer of 1 to 6, R.sup.21 and R.sup.22 when present are independently selected from the group consisting of hydrogen or lower alkyl, R.sup.23 when present is selected from the group consisting of hydroxyalkyl, alkoxyalkyl, alkyl, aryl, aralkyl and alkoxycarbonylalkyl, provided that when M.sup.3 is NR.sup.6, M.sup.4 is absent, and R.sup.12 is CONR.sup.22R.sup.23, then R.sup.23 is not 1-(1,3-benzodioxol-5-yl)-3-ethoxy-3-oxopropyl, R.sup.24 when present is selected from the group consisting of alkyl, aryl, aralkyl, heterocyclyl, cycloalkyl, cycloalkylalkyl, and heterocyclylalkyl, M.sup.6 is absent, (CH.sub.2).sub.q, (CH.sub.2).sub.q--CH.dbd.CH--(CH.sub.2).sub.r, (CH.sub.2).sub.q-arylene-(CH.sub.2)r and (CH.sub.2CH.sub.2O).sub.q, or NR.sup.34(CH.sub.2).sub.q, wherein q and r are integers independently having a value from 0 to 6, R.sup.3 is selected from the group consisting of hydrogen, CONR.sup.13R.sup.14, NR.sup.15COOR.sup.16, NR.sup.15COR.sup.16, NR.sup.15CONR.sup.13R.sup.14, NR.sup.15SO.sub.2R.sup.16, OCOR.sup.16, COOR.sup.16, OR.sup.16, SR.sup.16, heterocyclyl, hydroxyl, hydroxyalkyl, guanadino, alkyl and aryl, where R.sup.13 and R.sup.15 when present are independently hydrogen or lower alkyl, R.sup.14 and R.sup.16 when present are independently selected from the group consisting of hydrogen, alkyl, aryl, aralkyl, cycloalkyl, heterocyclyl, cycloalkylalkyl, and heterocyclylalkyl, R.sup.1, R.sup.2, R.sup.3, R.sup.12, R.sup.14, R.sup.16, R.sup.23, R.sup.24, and R.sup.34 when present may independently be either unsubstituted or substituted with one or more substituents selected from the group consisting of alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclylaryl, hydroxy, alkoxy, azido, haloalkoxy, hydroxyalkyl, aryloxy, hydroxyaryl, alkoxyaryl, halo, haloalkyl, haloaryl, amino, alkylamino, dialkylamino, arylamino, diarylamino, --NHCO(alkyl), --NHCO(aryl), --NHCO(aralkyl), --NHCO(haloalkyl), --NHSO.sub.2(alkyl), --NHSO.sub.2(aryl), --NHSO.sub.2(aralkyl), alkoxycarbonyl, alkoxycarbonylalkyl, --OCO(alkylamino), and --OCO(dialkylamino), wherein the compound or the compounds enhance an anti-tumor activity of the therapeutic antibody.

2. The composition of claim 1, wherein: R.sup.1 is aryl, R.sup.2 is aralkyl, M.sup.1 is CH.sub.2, M.sup.2 is CO, M.sup.3 is absent, M.sup.4 is absent, M.sup.5 is absent, M.sup.6 is (CH.sub.2).sub.q, q is an integer from 1 to 6, R.sup.3 is CONR.sup.13R.sup.14, and R.sup.13 and R.sup.14 are independently aralkyl.

3. The composition preparation of claim 2, wherein R.sup.1M.sup.1, R.sup.2, R.sup.13, and R.sup.14 are independently selected from the group consisting of 2-thienylmethyl, 3-methoxybenzyl, 4-methoxybenzyl, 2-(2-thienyl)ethyl, pyridin-4-ylmethyl, and pyridin-3-ylmethyl.

4. The composition of claim 3, wherein the chemical compounds are selected from the group consisting of N,N,N',N'-tetrakis(2-thienylmethyl)pentanediamide; N-(3-methoxybenzyl)-N,N',N'-tris(2-thienylmethyl)pentanediamide; N,N,N'-tris(2-thienylmethyl)pentanediamide; N'-[2-(2-thienyl)ethyl]-N,N-bis(2-thienylmethyl)pentanediamide; N-[2-(2-thienyl)ethyl]-N,N',N'-tris(2-thienylmethyl)pentanediamide; N,N-bis(pyridin-4-ylmethyl)-N',N'-bis(2-thienylmethyl)pentanediamide; N,N-bis(pyridin-3-ylmethyl)-N',N'-bis(2-thienylmethyl)pentanediamide; N,N-bis(3-methoxybenzyl)-N',N'-bis(2-thienylmethyl)pentanediamide; N,N,N',N'-tetrakis(4-methoxybenzyl)pentanediamide; N,N,N',N'-tetrakis(2-thienylmethyl)hexanediamide; N,N,N',N'-tetrakis(4-methoxybenzyl)hexanediamide; N,N,N',N'-tetrakis(3-methoxybenzyl)hexanediamide; N,N,N',N'-tetrakis(2-thienylmethyl)heptanediamide; 2,2'-(1,3-phenylene)bis[N,N-bis(2-thienylmethyl)acetamide]; N,N,N',N'-tetrakis(4-methoxybenzyl)heptanediamide; N,N,N',N'-tetrakis(2-thienylmethyl)octanediamide; (3E)-N,N,N',N'-tetrakis(2-thienylmethyl)hex-3-enediamide; 2,2'-oxybis[N,N-bis(2-thienylmethyl)acetamide]; 3-oxo-1-(2-thienyl)-2-(2-thienylmethyl)-4,7,10-trioxa-2-azadodecan-12-yl bis(2-thienylmethyl)carbamate; N,N,N',N'-tetrakis(4-methoxybenzyl)succinamideethane-1,2-diyl bis[bis(2-thienylmethyl)carbamate]; N,N,N',N'-tetrakis(4-methoxybenzyl)octanediamide; N,N,N',N'-tetrakis(2-thienylmethyl)pyridine-3,5-dicarboxamide; N,N,N',N'-tetrakis(2-thienylmethyl)pyridine-2,6-dicarboxamide; N,N,N',N'-tetrakis(2-thienylmethyl)pyridine-2,4-dicarboxamide; 2,2'-(1,4-phenylene)bis[N,N-bis(2-thienylmethyl)acetamide]; 8-{2-[bis(2-thienylmethyl)amino]-2-oxoethoxy}-N,N-bis(2-thienylmethyl)qui- noline-2-carboxamide; N,N'-bis(4-methoxybenzyl)-N,N'-bis(2-thienylmethyl)hexanediamide; and tert-butyl{(2S)-1,6-bis[bis(2-thienylmethyl)amino]-1,6-dioxohexan-2-yl}ca- rbamate.

5. The composition of claim 1, wherein: R.sup.1 is aryl, R.sup.2 is aralkyl, M.sup.1 is CH.sub.2, M.sup.2 is CO, M.sup.3 is O, M.sup.4 is absent, M.sup.5 is absent, M.sup.6 is (CH.sub.2CH.sub.2O).sub.q, q is an integer from 1 to 6, R.sup.3 is CONR.sup.13R.sup.14, and R.sup.13 and R.sup.14 are independently aralkyl.

6. The composition of claim 5, wherein R.sup.1M.sup.1, R.sup.2, R.sup.13, and R.sup.14 are independently selected from the group consisting of 2-thienylmethyl, 3-methoxybenzyl, 4-methoxybenzyl, 2-(2-thienyl)ethyl, pyridin-4-ylmethyl, and pyridin-3-ylmethyl.

7. The composition of claim 6, wherein the chemical compounds are selected from the group consisting of 1,2-bis(bis(thiophen-2-ylmethyl)carbamate)ethane; 1,2-bis(bis(3-methyloxybenzyl)carbamate)ethane; 1,2-bis(bis(4-methyloxybenzyl)carbamate)ethane; 1,2-bis((thiophen-2-ylmethyl)(3-methyloxybenzyl)carbamate)ethane; 1,2-bis((thiophen-2-ylmethyl)(4-methyloxybenzyl)carbamate)ethane; 1,2-bis((3-methyloxybenzyl)(4-methyloxybenzyl)carbamate)ethane; 1,5-bis(bis(thiophen-2-ylmethyl)carbamate)-3-oxapentane; 1,5-bis(bis(3-methyloxybenzyl)carbamate)-3-oxapentane; 1,5-bis(bis(4-methyloxybenzyl)carbamate)-3-oxapentane; 1,5-bis((thiophen-2-ylmethyl)(3-methyloxybenzyl)carbamate)-3-oxapentane; 1,5-bis((thiophen-2-ylmethyl)(4-methyloxybenzyl)carbamate)-3-oxapentane; 1,5-bis((3-methyloxybenzyl)(4-methyloxybenzyl)carbamate)-3-oxapentane; (ethane-1,2-diylbis(oxy))bis(ethane-2,1-diyl)bis(bis(thiophen-2-ylmethyl)- carbamate) or 1,8-bis(bis(thiophen-2-ylmethyl)carbamate)-3,6-dioxaoctane; 1,8-bis(bis(3-methyloxybenzyl)carbamate)-3,6-dioxaoctane; 1,8-bis(bis(4-methyloxybenzyl)carbamate)-3,6-dioxaoctane; 1,8-bis((thiophen-2-ylmethyl)(3-methyloxybenzyl)carbamate)-3,6-dioxaoctan- e; 1,8-bis((thiophen-2-ylmethyl)(4-methyloxybenzyl)carbamate)-3,6-dioxaoct- ane; 1,8-bis((3-methyloxybenzyl)(4-methyloxybenzyl)carbamate)-3,6-dioxaoct- ane; 1,11-bis(bis(thiophen-2-ylmethyl)carbamate)-3,6,9-trioxaundecane; 1,11-bis(bis(3-methyloxybenzyl)carbamate)-3,6,9-trioxaundecane; 1,11-bis(bis(4-methyloxybenzyl)carbamate)-3,6,9-trioxaundecane; 1,11-bis((thiophen-2-ylmethyl)(3-methyloxybenzyl)carbamate)-3,6,9-trioxau- ndecane; 1,11-bis((thiophen-2-ylmethyl)(4-methyloxybenzyl)carbamate)-3,6,9- -trioxaundecane; 1,11-bis((3-methyloxybenzyl)(4-methyloxybenzyl)carbamate)-3,6,9-trioxaund- ecane; 1,14-bis(bis(thiophen-2-ylmethyl)carbamate)-3,6,9,12-tetraoxatetrad- ecane; 1,14-bis(bis(3-methyloxybenzyl)carbamate)-3,6,9,12-tetraoxatetradec- ane; 1,14-bis(bis(4-methyloxybenzyl)carbamate)-3,6,9,12-tetraoxatetradecan- e; 1,14-bis((thiophen-2-ylmethyl)(3-methyloxybenzyl)carbamate)-3,6,9,12-te- traoxatetradecane; 1,14-bis((thiophen-2-ylmethyl)(4-methyloxybenzyl)carbamate)-3,6,9,12-tetr- aoxatetradecane; 1,14-bis((3-methyloxybenzyl)(4-methyloxybenzyl)carbamate)-3,6,9,12-tetrao- xatetradecane; 1,17-bis(bis(thiophen-2-ylmethyl)carbamate)-3,6,9,12,15-pentaoxatetradeca- ne; 1,17-bis(bis(3-methyloxybenzyl)carbamate)-3,6,9,12,15-pentaoxatetradec- ane; 1,17-bis(bis(4-methyloxybenzyl)carbamate)-3,6,9,12,15-pentaoxatetrade- cane; 1,17-bis((thiophen-2-ylmethyl)(3-methyloxybenzyl)carbamate)-3,6,9,12- ,15-pentaoxatetradecane; 1,17-bis((thiophen-2-ylmethyl)(4-methyloxybenzyl)carbamate)-3,6,9,12,15-p- entaoxatetradecane; 1,17-bis((3-methyloxybenzyl)(4-methyloxybenzyl)carbamate)-3,6,9,12,15-pen- taoxatetradecane.

8. The composition of claim 1, wherein: R.sup.1 is aryl, R.sup.2 is aralkyl, M.sup.1 is CH.sub.2, M.sup.2 is CO, M.sup.3 is O, M.sup.4 is CH.sub.2, M.sup.5 is CR.sup.11R.sup.12, R.sup.11 is hydrogen and R.sup.12 is alkyl, M.sup.6 is absent, R.sup.3 is NR.sup.15CONR.sup.13R.sup.14, R.sup.13 and R.sup.15 are hydrogen, and R.sup.14 is heterocyclylalkyl.

9. The composition of claim 8, wherein R.sup.1M.sup.1, R.sup.2, R.sup.13, and R.sup.14 are independently selected from the group consisting of 2-thienylmethyl, 3-methoxybenzyl, 4-methoxybenzyl, 2-(2-thienyl)ethyl, pyridin-4-ylmethyl, and pyridin-3-ylmethyl.

10. The composition of claim 9, wherein the chemical compounds are selected from the group consisting of methyl (6S,10S)-10-(1,3-benzodioxol-5-yl)-6-butyl-3,8-dioxo-1-(2-thienyl)-2-(2-t- hienylmethyl)-4-oxa-2,7,9-triazadodecan-12-oate; methyl (6S,10R)-10-(1,3-benzodioxol-5-yl)-6-butyl-3,8-dioxo-1-(2-thienyl)-2-(2-t- hienylmethyl)-4-oxa-2,7,9-triazadodecan-12-oate; methyl (6S,10S)-10-(1,3-benzodioxol-5-yl)-6-butyl-7-methyl-3,8-dioxo-1-(2-thieny- l)-2-(2-thienylmethyl)-4-oxa-2,7,9-triazadodecan-12-oate; methyl (6S,10S)-10-(1,3-benzodioxol-5-yl)-6-butyl-9-methyl-3,8-dioxo-1-(2-thieny- l)-2-(2-thienylmethyl)-4-oxa-2,7,9-triazadodecan-12-oate; ethyl (6S,10R)-10-(1,3-benzodioxol-5-yl)-6-butyl-7-methyl-3,8-dioxo-1-(2-thieny- l)-2-(2-thienylmethyl)-4-oxa-2,7,9-triazadodecan-12-oate; methyl (10S)-10-(1,3-benzodioxol-5-yl)-3,8-dioxo-1-(2-thienyl)-2-(2-thienylmethy- l)-4-oxa-2,7,9-triazadodecan-12-oate; methyl 3,8-dioxo-1-(2-thienyl)-2-(2-thienylmethyl)-4-oxa-2,7,9-triazadodecan-12-- oate; methyl (6S,10S)-10-(1,3-benzodioxol-5-yl)-6-butyl-2-methyl-3,8-dioxo-1-(2-thieny- l)-4-oxa-2,7,9-triazadodecan-12-oate; methyl (6S)-6-butyl-3,8-dioxo-1-(2-thienyl)-2-(2-thienylmethyl)-4-oxa-2,7,9-tria- zadodecan-12-oate; (2S)-2-{[(1,3-benzodioxol-5-ylmethyl)carbamoyl]amino}hexyl bis(2-thienylmethyl)carbamate; methyl (6S,10S)-6-butyl-3,8-dioxo-10-phenyl-1-(2-thienyl)-2-(2-thienylmethyl)-4-- oxa-2,7,9-triazadodecan-12-oate; (2S)-2-({[(1S)-1-(1,3-benzodioxol-5-yl)-3-hydroxypropyl]carbamoyl}amino)h- exylbis(2-thienylmethyl)carbamate; (2S)-2-[(benzylcarbamoyl)amino]hexyl bis(2-thienylmethyl)carbamate; (2S)-2-[(morpholin-4-ylcarbonyl)amino]hexylbis(2-thienylmethyl)carbamate; (2S)-2-{[(3-methoxypropyl)carbamoyl]amino}hexylbis(2-thienylmethyl)carbam- ate; (2S)-2-{[(2-methoxyethyl)carbamoyl]amino}hexyl bis(2-thienylmethyl)carbamate; tert-butyl [(2S)-1-{[bis(2-thienylmethyl)carbamoyl]oxy}hexan-2-yl]carbamate; (2S)-2-[(tert-butylcarbamoyl)amino]hexyl bis(2-thienylmethyl)carbamate; (2S)-2-[(isopropylcarbamoyl)amino]hexylbis(2-thienylmethyl)carbamate; (2S)-2-[(methylcarbamoyl)amino]hexyl bis(2-thienylmethyl)carbamate; tert-butyl [(2R)-1-{[bis(2-thienylmethyl)carbamoyl]oxy}hexan-2-yl]carbamate; benzyl {(5S)-6-{[bis(2-thienylmethyl)carbamoyl]oxy}-5-[(tert-butoxycarbonyl)amin- o]hexyl}carbamate; methyl(9S,13S)-13-(1,3-benzodioxol-5-yl)-9-({[bis(2-thienylmethyl)carbamo- yl]oxy}methyl)-3,11-dioxo-1-phenyl-2-oxa-4,10,12-triazapentadecan-15-oate; (2S)-2-acetamidohexylbis(2-thienylmethyl)carbamate; methyl(6R,10S)-10-(1,3-benzodioxol-5-yl)-6-butyl-3,8-dioxo-1-(2-thienyl)-- 2-(2-thienylmethyl)-4-oxa-2,7,9-triazadodecan-12-oate; methyl (6R,10R)-10-(1,3-benzodioxol-5-yl)-6-butyl-3,8-dioxo-1-(2-thienyl)-2-(2-t- hienylmethyl)-4-oxa-2,7,9-triazadodecan-12-oate; methyl {[bis(2-thienylmethyl)carbamoyl](methyl)amino}acetate; methyl {[bis(2-thienylmethyl)carbamoyl](butyl)amino}acetate; tert-butyl {[bis(2-thienylmethyl)carbamoyl](butyl)amino}acetate; benzyl {(5S)-6-{[bis(4-methoxybenzyl)carbamoyl]oxy}-5-[(tert-butoxycarbonyl)amin- o]hexyl}carbamate; tert-butyl [(2S)-1-{[bis(4-methoxybenzyl)carbamoyl]oxy}hexan-2-yl]carbamate; methyl (6S,10S)-10-(1,3-benzodioxol-5-yl)-6-butyl-2-(4-methoxybenzyl)-1-(4-metho- xyphenyl)-3,8-dioxo-4-oxa-2,7,9-triazadodecan-12-oate; (2S)-2-({[(1S)-1-(1,3-benzodioxol-5-yl)-3-hydroxypropyl]carbamoyl}amino) hexyl bis(4-methoxybenzyl)carbamate; (2S)-2-[(tertbutoxycarbonyl)amino]hexyl dibenzylcarbamate; methyl (6S,10S)-10-(1,3-benzodioxol-5-yl)-2-benzyl-6-butyl-3,8-dioxo-1-phenyl-4-- oxa-2,7,9-triazadodecan-12-oate; tert-butyl [(2S)-1-{[bis(4-methylbenzyl)carbamoyl]oxy}hexan-2-yl]carbamate; methyl (6S,10S)-10-(1,3-benzodioxol-5-yl)-6-butyl-2-(4-methylbenzyl)-1-(4-methyl- phenyl)-3,8-dioxo-4-oxa-2,7,9-triazadodecan-12-oate; tert-butyl[(2S)-1-{[bis(4-chlorobenzyl)carbamoyl]oxy}hexan-2-yl]carbamate- ; methyl (6S,10S)-10-(1,3-benzodioxol-5-yl)-6-butyl-2-(4-chlorobenzyl)-1-(- 4-chlorophenyl)-3,8-dioxo-4-oxa-2,7,9-triazadodecan-12-oate; (2S)-2-[(tertbutoxycarbonyl)amino]hexyl (4-bromobenzyl)(2-thienylmethyl)carbamate; methyl (6S,10S)-10-(1,3-benzodioxol-5-yl)-2-(4-bromobenzyl)-6-butyl-3,8-dioxo-1-- (2-thienyl)-4-oxa-2,7,9-triazadodecan-12-oate; methyl (6S,10S)-2-(4-azidobenzyl)-10-(1,3-benzodioxol-5-yl)-6-butyl-3,8-dioxo-1-- (2-thienyl)-4-oxa-2,7,9-triazadodecan-12-oate; (2S)-2-[(tert-butoxycarbonyl)amino]hexyl phenyl(2-thienylmethyl)carbamate; methyl (6S,10S)-10-(1,3-benzodioxol-5-yl)-6-butyl-3,8-dioxo-2-phenyl-1-(2-thieny- l)-4-oxa-2,7,9-triazadodecan-12-oate; tert-butyl [(2S)-1-{[bis(3-thienylmethyl)carbamoyl]oxy}hexan-2-yl]carbamate; methyl (6S,10S)-10-(1,3-benzodioxol-5-yl)-6-butyl-3,8-dioxo-1-(3-thienyl)-2-(3-t- hienylmethyl)-4-oxa-2,7,9-triazadodecan-12-oate; benzyl [(5S)-5-[(tertbutoxycarbonyl)amino]-6-{[butyl (2-thienylmethyl)carbamoyl]oxy}hexyl]carbamate; (2S)-2-[(tert-butoxycarbonyl)amino]hexylbutyl(2-thienylmethyl)carbamate; methyl (3S,7S)-3-(1,3-benzodioxol-5-yl)-7-butyl-5,11-dioxo-11-(2-thienylm- ethyl)-9-oxa-4,6,11-triazapentadecan-1-oate; benzyl [(5S)-5-[(tert-butoxycarbonyl)amino]-6-{[(2-methoxyethyl)(2-thienylmethyl- )carbamoyl]oxy}hexyl]carbamate; (2S)-2-[(tert-butoxycarbonyl)amino]hexyl (2-methoxyethyl)(2-thienylmethyl)carbamate; methyl (9S,13S)-13-(1,3-benzodioxol-5-yl)-9-butyl-6,11-dioxo-5-(2-thienylmethyl)- -2,7-dioxa-5,10,12-triazapentadecan-15-oate; (2S)-2-[({3-[(methylsulfonyl)amino]benzyl}carbamoyl)amino]hexyl(2-methoxy- ethyl)(2-thienylmethyl)carbamate; (2S)-2-{[(4-bromobenzyl)carbamoyl]amino}hexylbis(2-thienylmethyl)carbamat- e; (2S)-2-{[(4-azidobenzyl)carbamoyl]amino}hexylbis(2-thienylmethyl)carbam- ate; tert-butyl[(2S)-1-{[bis(2-thienylmethyl)carbamoyl]thio}hexan-2-yl]car- bamate; and methyl (6S,10S)-10-(1,3-benzodioxol-5-yl)-6-butyl-3,8-dioxo-1-(2-thienyl)-2-(2-t- hienylmethyl)-4-thia-2,7,9-triazadodecan-12-oate.

11. The composition of claim 1, wherein: R.sup.1 is aryl, R.sup.2 is aralkyl, M.sup.1 is CH.sub.2, M.sup.2 is SO.sub.2, M.sup.3 is CH.sub.2, M.sup.4 is CH.sub.2, M.sup.5 is absent, M.sup.6 is NR.sup.34(CH.sub.2).sub.q, q is an integer from 2 to 6, R.sup.34 is alkyl, R.sup.3 is CONR.sup.13R.sup.14, and R.sup.13 and R.sup.14 are independently aralkyl.

12. The composition of claim 11, wherein R.sup.1M.sup.1, R.sup.2, R.sup.13, and R.sup.14 are independently selected from the group consisting of 2-thienylmethyl, 3-methoxybenzyl, 4-methoxybenzyl, 2-(2-thienyl)ethyl, pyridin-4-ylmethyl, and pyridin-3-ylmethyl.

13. The composition of claim 12, wherein the chemical compounds are selected from the group consisting of N-{2-[bis(2-thienylmethyl)sulfamoyl]ethyl}-N-(2-thienylmethyl)thiophene-2- -sulfonamide; N-{2-[bis(2-thienylmethyl)sulfamoyl]ethyl}-N-(2-thienylmethyl)thiophene-2- -carboxamide; 2-{butyl[(2-thienylmethyl)carbamoyl]amino}-N,N-bis(2-thienylmethyl)ethane- sulfonamide; 2-{[bis(2-thienylmethyl)carbamoyl](butyl)amino}-N,N-bis(2-thienylmethyl)e- thanesulfonamide; N-{3-[bis(2-thienylmethyl)sulfamoyl]propyl}-N-(2-thienylmethyl)thiophene-- 2-sulfonamide; 2-[(methylsulfonyl)(2-thienylmethyl)amino]-N,N-bis(2-thienylmethyl)ethane- sulfonamide; 2-{[bis(2-thienylmethyl)carbamoyl]amino}-N,N-bis(2-thienylmethyl)ethanesu- lfonamide; N-{2-[bis(2-thienylmethyl)sulfamoyl]ethyl}thiophene-2-sulfonami- de; N-{2-[bis(2-thienylmethyl)sulfamoyl]ethyl}-2-(2-thienyl)acetamide; N-{2-[bis(2-thienylmethyl)sulfamoyl]ethyl}thiophene-2-carboxamide; N,N-bis(2-thienylmethyl)-2-{[(2-thienylmethyl)carbamoyl]amino}ethanesulfo- namide; 2-({2-[bis(2-thienylmethyl)sulfamoyl]ethyl}amino)-N,N-bis(2-thieny- lmethyl)acetamide; 3-[{2-[bis(2-thienylmethyl)amino]-2-oxoethyl}(butyl)amino]-N,N-bis(2-thie- nylmethyl)propanamide; 2-[{2-[bis(2-thienylmethyl)sulfamoyl]ethyl}(methyl)amino]-N,N-bis(2-thien ylmethyl)acetamide; 2-[{2-[bis(2-thienylmethyl)sulfamoyl]ethyl}(butyl)amino]-N,N-bis(2-thieny- lmethyl)acetamide; 3-({2-[bis(2-thienylmethyl)sulfamoyl]ethyl}amino)-N,N-bis(2-thienylmethyl- )propanamide; 3-({2-[bis(2-thienylmethyl)sulfamoyl]ethyl}amino)-N,N-bis(4-methoxybenzyl- )propanamide; 3-({2-[bis(4-methoxybenzyl)sulfamoyl]ethyl}amino)-N,N-bis(2-thienylmethyl- )propanamide; 3-[{2-[bis(2-thienylmethyl)sulfamoyl]ethyl}(methyl)amino]-N,N-bis(2-thien- ylmethyl)propanamide; 3-[{2-[bis(4-methoxybenzyl)sulfamoyl]ethyl}(methyl)amino]-N,N-bis(2-thien- ylmethyl) propanamide; (2S)-2-({2-[bis(2-thienylmethyl)sulfamoyl]ethyl}amino)-N,N-bis(2-thienylm- ethyl) hexanamide; (2S)-2-({2-[bis(4-methoxybenzyl)sulfamoyl]ethyl}amino)-N,N-bis(2-thienylm- ethyl) hexanamide; 2-(acetyl {2-[bis(2-thienylmethyl)sulfamoyl]ethyl}amino)-N,N-bis(2-thienylmethyl) acetamide; 2-(acetyl {2-[bis(4-methoxybenzyl)sulfamoyl]ethyl}amino)-N,N-bis(2-thienyl-methyl) acetamide; pharmaceutically acceptable salts thereof, and mixtures or combinations thereof.

14. The composition of claim 1, wherein the therapeutic antibody is present in a therapeutically ineffective amount and the compound or the compounds are present in an amount sufficient to render the ineffective amount of the therapeutic antibody therapeutically effective and wherein the amount of the compound or the compounds is between 1 fM and 10 .mu.M.

15. The composition of claim 1, wherein the therapeutic antibody is selected from the group consisting of trastuzumab, cetuximab, ipilimumab, nivolumab rituximab, alemtuzumab, atumumab, and/or tositumomab.

16. The composition of claim 2, wherein: the therapeutic antibody is present in a therapeutically ineffective amount and the compound or the compounds are present in an amount sufficient to render the ineffective amount of the therapeutic antibody therapeutically effective, the amount of the compound or the compounds is between 1 fM and 10 .mu.M, and the therapeutic antibody selected from the group consisting of trastuzumab, cetuximab, ipilimumab, nivolumab, rituximab, alemtuzumab, atumumab, and/or tositumomab.

17. The composition of claim 5, wherein: the therapeutic antibody is present in a therapeutically ineffective amount and the compound or the compounds are present in an amount sufficient to render the ineffective amount of the therapeutic antibody therapeutically effective, the amount of the compound or the compounds is between 1 fM and 10 .mu.M, and the therapeutic antibody selected from the group consisting of trastuzumab, cetuximab, ipilimumab, nivolumab, rituximab, alemtuzumab, atumumab, and/or tositumomab.

18. The composition of claim 8, wherein: the therapeutic antibody is present in a therapeutically ineffective amount and the compound or the compounds are present in an amount sufficient to render the ineffective amount of the therapeutic antibody therapeutically effective, the amount of the compound or the compounds is between 1 fM and 10 .mu.M, and the antibody is selected from the group consisting of trastuzumab, cetuximab, ipilimumab, nivolumab, rituximab, alemtuzumab, atumumab, and/or tositumomab.

19. The composition of claim 11, wherein: the therapeutic antibody is present in a therapeutically ineffective amount and the compound or the compounds are present in an amount sufficient to render the ineffective amount of the therapeutic antibody therapeutically effective, the amount of the compound or the compounds is between 1 fM and 10 .mu.M, and the therapeutic antibody is selected from the group consisting of trastuzumab, cetuximab, ipilimumab, nivolumab, rituximab, alemtuzumab, atumumab, and/or tositumomab.

20. A pharmaceutical composition comprising: one integrin activating compound or a plurality of integrin activating compounds capable of enhancing an anti-tumor activity of an immune checkpoint inhibitor antibody.

21. The composition of claim 20, wherein: the compound or compounds are of the general Formula (I): R.sup.1-M.sup.1-N(R.sup.2)-M.sup.2-M.sup.3-M.sup.4-M.sup.5-M.sup.6-R.sup.- 3 (I) wherein: R.sup.1 is selected from the group consisting of aryl and aralkyl, R.sup.2 is alkyl, aryl, or aralkyl, M.sup.1 is CH.sub.2, M.sup.2 is CO, M.sup.3 is O, S, or NR.sup.6, where R.sup.6 when present is hydrogen or lower alkyl, M.sup.4 is absent or CH.sub.2, M.sup.5 is absent or (CR.sup.11R.sup.12) where R.sup.11 is hydrogen, R.sup.12 is selected from the group consisting of hydrogen, NR.sup.21CONR.sup.22R.sup.23, NR.sup.21COR.sup.24, NR.sup.21SO.sub.2R.sup.24, NR.sup.21COOR.sup.24, OCOR.sup.24, OR.sup.24, O(CH.sub.2CH.sub.2O).sub.sR.sup.24, COOR.sup.24, alkyl, and hydroxyalkyl, where s is an integer of 1 to 6, R.sup.21 and R.sup.22 when present are independently selected from the group consisting of hydrogen or lower alkyl, R.sup.23 when present is selected from the group consisting of hydroxyalkyl, alkoxyalkyl, alkyl, aryl, aralkyl and alkoxycarbonylalkyl, provided that when M.sup.3 is NR.sup.6, M.sup.4 is absent, and R.sup.12 is CONR.sup.22R.sup.23, then R.sup.23 is not 1-(1,3-benzodioxol-5-yl)-3-ethoxy-3-oxopropyl, R.sup.24 when present is selected from the group consisting of alkyl, aryl, aralkyl, heterocyclyl, cycloalkyl, cycloalkylalkyl, and heterocyclylalkyl, M.sup.6 is absent, (CH.sub.2).sub.q, (CH.sub.2).sub.q--CH.dbd.CH--(CH.sub.2).sub.r, (CH.sub.2).sub.q-arylene-(CH.sub.2)r and (CH.sub.2CH.sub.2O).sub.q, or NR.sup.34(CH.sub.2).sub.q, wherein q and r are integers independently having a value from 0 to 6, R.sup.3 is selected from the group consisting of hydrogen, CONR.sup.13R.sup.14, NR.sup.15COOR.sup.16, NR.sup.15COR.sup.16, NR.sup.15CONR.sup.13R.sup.14, NR.sup.15SO.sub.2R.sup.16, OCOR.sup.16, COOR.sup.16, OR.sup.16, SR.sup.16, heterocyclyl, hydroxyl, hydroxyalkyl, guanadino, alkyl and aryl, where R.sup.13 and R.sup.15 when present are independently hydrogen or lower alkyl, R.sup.14 and R.sup.16 when present are independently selected from the group consisting of hydrogen, alkyl, aryl, aralkyl, cycloalkyl, heterocyclyl, cycloalkylalkyl, and heterocyclylalkyl, R.sup.1, R.sup.2, R.sup.3, R.sup.12, R.sup.14, R.sup.16, R.sup.23, R.sup.24, and R.sup.34 when present may independently be either unsubstituted or substituted with one or more substituents selected from the group consisting of alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclylaryl, hydroxy, alkoxy, azido, haloalkoxy, hydroxyalkyl, aryloxy, hydroxyaryl, alkoxyaryl, halo, haloalkyl, haloaryl, amino, alkylamino, dialkylamino, arylamino, diarylamino, --NHCO(alkyl), --NHCO(aryl), --NHCO(aralkyl), --NHCO(haloalkyl), --NHSO.sub.2(alkyl), --NHSO.sub.2(aryl), --NHSO.sub.2(aralkyl), alkoxycarbonyl, alkoxycarbonylalkyl, --OCO(alkylamino), and --OCO(dialkylamino).

22. The composition of claim 20, wherein: the immune checkpoint inhibitor antibody is present in a subtherapeutic amount and the compound or the compounds are present in an amount sufficient to render the subtherapeutic amount of the immune checkpoint inhibitor antibody therapeutically effective, and the amount of the compound or the compounds is between 1 fM and 10 .mu.M.

23. The composition of claim 20, wherein: the immune checkpoint inhibitor antibody is selected from the group consisting of ipilimumab and/or nivolumab, and the integrins are selected from the group consisting of .alpha.4.beta.1, .alpha.4.beta.7, .alpha.5.beta.1, and/or .alpha.L.beta.2.

Details for Patent 10,342,866

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. RITUXAN rituximab Injection 103705 11/26/1997 ⤷  Try a Trial 2035-04-29
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 09/25/1998 ⤷  Try a Trial 2035-04-29
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 02/10/2017 ⤷  Try a Trial 2035-04-29
Genzyme Corporation CAMPATH alemtuzumab Injection 103948 05/07/2001 ⤷  Try a Trial 2035-04-29
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.